This nonsense about marketing and partnering is ut
Post# of 148176
Quote:
However, I'm not sure Daiichi Sankyo would have the marketing sale force necessary to promote, sell, and distribute leronolimab for the Combo HIV indication (followed, of course, by Mono).
Given the options, I would think an international sales and distribution deal with a Big Pharma would offer more advantages, and a consolidation of the entire supply chain under one banner. But that's an uneducated assumption on my part.
Get bent, pharma moles